BioAge Stock Surges 14% Following Collaboration with Novartis

BioAge Stock Surges 14% Following Collaboration with Novartis

BioAge Labs saw its stock price climb 14% to $4.67 on Wednesday after announcing a research partnership with the Swiss biopharmaceutical company Novartis. The collaboration could potentially bring BioAge up to $550 million in funding and milestone payments.

This rebound offers some relief after BioAge’s shares plunged by 76% on December 6, following the decision to halt a phase-two trial for its obesity treatment.

Focus of the Collaboration

The partnership will involve a multi-year research initiative to explore the mechanisms behind aging-related diseases and how physical exercise contributes to longevity. BioAge plans to leverage its extensive human longevity datasets alongside Novartis’s expertise in exercise biology to identify and develop new therapeutic targets.

Financial Terms

As part of the agreement:

BioAge will receive upfront research funding and up to $20 million in initial payments.

The deal includes an additional $530 million in potential milestone payments tied to research, development, and commercialization achievements.

Both companies retain the rights to advance any novel targets discovered during the collaboration.

This strategic partnership underscores the growing interest in aging research and positions BioAge to make significant advancements in the field.